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Abstract
Experimental obstacles have impeded our ability to study prion transmission within and, more particularly, between species.
Here, we used cervid prion protein expressed in brain extracts of transgenic mice, referred to as Tg(CerPrP), as a substrate
for in vitro generation of chronic wasting disease (CWD) prions by protein misfolding cyclic amplification (PMCA).
Characterization of this infectivity in Tg(CerPrP) mice demonstrated that serial PMCA resulted in the high fidelity
amplification of CWD prions with apparently unaltered properties. Using similar methods to amplify mouse RML prions and
characterize the resulting novel cervid prions, we show that serial PMCA abrogated a transmission barrier that required
several hundred days of adaptation and subsequent stabilization in Tg(CerPrP) mice. While both approaches produced
cervid prions with characteristics distinct from CWD, the subtly different properties of the resulting individual prion isolates
indicated that adaptation of mouse RML prions generated multiple strains following inter-species transmission. Our studies
demonstrate that combined transgenic mouse and PMCA approaches not only expedite intra- and inter-species prion
transmission, but also provide a facile means of generating and characterizing novel prion strains.
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Introduction
Prion diseases are transmissible, fatal, and incurable neurode-
generative disorders of the central nervous system (CNS) that
include bovine spongiform encephalopathy (BSE), ovine scrapie,
chronic wasting disease (CWD) of cervids and human Creutzfeldt-
Jakob disease (CJD). While inoculation of diseased brain material
into individuals of the same species typically reproduces disease,
studies of prion transmissions are complicated by prolonged,
clinically silent incubation periods lasting months to years. Inter-
species prion transmission is generally an even less efficient
process, a phenomenon referred to as the species barrier [1].
While studies in transgenic (Tg) mice [2–6] and cell-free systems
[7], demonstrated the influence of PrP primary structure on prion
transmission, agent strain properties are an equally important
determinant. Thus, the time between inoculation and onset of
clinical signs, referred to as the incubation time, is a parameter
that varies between strains. Different strains may also induce
distinct clinical signs in inoculated animals. Neuropathologically,
strains are distinguished by reproducible differences in the
distribution of spongiform degeneration of the cerebral grey
matter, and by the deposition of PrPSc, occasionally in the form of
amyloid plaques. While the different strain properties of
conventional pathogens are genomically encoded, it is less clear
how multiple disease phenotypes can be accommodated in the
context of a ‘protein only’ mechanism of pathogenesis where the
infectious agent lacks nucleic acid. Numerous studies suggest that
strain diversity is enciphered in the higher order structure of PrPSc
[8–12]; accordingly, the biochemical properties of PrPSc have also
been used as a means of typing prion isolates [13,14].
While prion strain properties are stably maintained upon
passage within a particular species, inter-species prion transmission
may result in the acquisition of new strain properties, the most
profound of which may be host range alteration [15,16]. Thus, the
species tropism of novel prion strains currently cannot be
predicted. A powerful demonstration of the unpredictable
influence of prion strains on species barriers is highlighted in the
case of BSE. Cattle feed derived from rendered meat and bone
meal which was contaminated with prions, possibly originating
from scrapie-infected sheep, is the suspected origin of BSE [17].
BSE-related prion diseases were subsequently identified in
domestic and captive wild cats [18,19] and exotic ungulates.
The recognition that a variant of CJD (vCJD) is caused by the BSE
prion strain [20–23] raised major public health concerns. Like
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BSE, the origin of transmissible mink encephalopathy (TME) of
ranch-raised mink, is thought to be prion-contaminated feed [24].
Recent years have witnessed the emergence of additional novel
mammalian prion strains. Atypical scrapie is a recently-recognized
and surprisingly prevalent prion disease of sheep of unknown
origin and host-range. First reported in Norwegian sheep in 2003
and referred to as Nor98 [25], atypical scrapie appears to be a
single, unique scrapie strain [26,27] infecting sheep with PRNP
genotypes usually associated with resistance to classical scrapie.
The increasing geographic range, contagious transmission,
uncertain strain prevalence, and environmental persistence of
CWD are also of concern. Uncontrolled prion dissemination in
wild cervid populations brings into question the risk of
transmission to other species, for example via shared grazing of
CWD-contaminated rangeland. Insights into the factors control-
ling prion transmission and host-range adaptation are clearly of
paramount importance for containing further prion epidemics.
The aim of this study was to evaluate the feasibility of expediting
studies of intra-, and inter-species prion transmission by combining
the resources of protein misfolding cyclic amplification (PMCA)
[28] with Tg mouse models of prion disease. During PMCA, the
normal form of PrP, referred to as PrPC, is converted into
protease-resistant PrP using small amounts of infectious PrPSc.
Continued recruitment and conversion of PrPC by PrPSc is
accomplished by sonication in a process analogous to amplification
of DNA by the polymerase chain reaction [29]. We previously
showed that Tg mice expressing PrP from mule deer, referred to as
Tg(CerPrP) mice, are susceptible to prions from deer and elk dying
of CWD [30–32]. Several other groups subsequently confirmed
these observations using similar mouse models [33–37]. Here we
used cervid PrPC (CerPrPC) expressed in the brains of Tg mice for
the generation of CWD prions by PMCA. Using Tg(CerPrP) mice
to characterize this in vitro-generated infectivity we demonstrate
that PMCA results in the high fidelity amplification of CWD
prions with apparently unaltered strain properties. In addition,
while adaptation of mouse prions to form novel cervid prions
required several hundred days in Tg(CerPrP) mice, we show that
PMCA abrogated this barrier to prion transmission resulting in the
rapid generation of novel cervid prions with similar properties.
Results
Serial PMCA of CWD-seeded CerPrPC from Tg(CerPrP)
mice results in high fidelity CWD prion replication
A PMCA reaction was established using a CWD prion seed in a
10% brain homogenate from diseased mule deer 04-22412, diluted
10-fold into 10% brain homogenate prepared from perfused
Tg(CerPrP)1536+/2 mice [30]. Following a round of PMCA
consisting of alternating periods of sonication and incubation for
36 cycles, the product, which contained amplified protease-resistant
CerPrP (Fig. 1A), was diluted 10-fold into another reaction
containing CerPrPC from Tg(CerPrP)1536+/2 mouse brain homog-
enate for a further round of PMCA. This process of serial PMCA
was repeated for 22 rounds. In accordance with previous studies
using the experimentally-adapted hamster scrapie isolate 263K
[38,39], and the experimentally-adapted Chandler scrapie isolate
[40], protease-resistant CerPrP was amplified to high levels during
each round of serial PMCA (Fig. 1A and C). In contrast, after 10
rounds of serial PMCA of six duplicated samples of a healthy
Tg(CerPrP)1536+/2 brain extract, no protease-resistant PrP was
produced in the absence of prion seeds (data not shown).
To ascertain whether this process resulted in the in vitro
amplification of CWD prions, Tg(CerPrP)1536+/2 mice were
intracerebrally challenged with the product of 22 rounds of serial
PMCA (Fig. 1C). A separate cohort was inoculated with a 1%
brain homogenate of the CWD-infected 04-22412 mule deer
isolate that was the seed for the initial round of PMCA. In both
cases, Tg(CerPrP)1536+/2 mice were inoculated with preparations
containing similar amounts of protease-resistant CerPrP, as
determined by Western blot analysis (Fig. 1C). Serial PMCA
reactions initially seeded with 04-22412 CWD prions but using
Prnp0/0 knockout instead of Tg(CerPrP)1536+/2 mouse brain
homogenate were also performed in parallel. A cohort of
Tg(CerPrP)1536+/2 mice inoculated with this material after 22
rounds of serial PMCA served as negative controls to show that the
original CWD inoculum was not detectable.
All Tg(CerPrP)1536+/2 mice (n= 6) inoculated with material
derived from serial PMCA of 04-22412 CWD prions using CerPrPC
from the brains of Tg(CerPrP)1536+/2 mice developed disease with
a mean incubation time of 263628 (mean6standard error) days (d)
(Fig. 2). Consistent with previous results [30–32], CWD prions from
the brain of diseased 04-22412 mule deer also induced disease in
Tg(CerPrP)1536+/2 mice (n=6) with an incubation time of
284622 d. The clinical signs that accompanied prion disease were
identical in both cases, and included truncal ataxia and slowed
movement, increased tone of the tail, dorsal kyphosis, head bobbing
or tilting, and roughened coat. Confirming that prion infectivity
produced by 22 rounds of serial PMCA was unrelated to persistence
of the initial 04-22412 CWD prion seed, no disease was registered in
Tg(CerPrP)1536+/2 mice inoculated with preparations from the
negative control reaction in which 04-22412 CWD prions were
seeded into Prnp0/0 brain homogenate followed by 22 rounds serial
PMCA (Fig. 2). Detection of CerPrPSc in the brains of diseased
Tg(CerPrP)1536+/2mice byWestern blotting (Fig. 3A), histoblotting
(Fig. 4), and immunohistochemical analysis (Fig. 5B–E) confirmed
that the clinical signs following inoculation with CWD prions or the
amplified samples were the consequence of prion disease. Collec-
tively these results demonstrate that serial PMCA resulted in the
efficient in vitro production of infectious CWD prions. We therefore
refer to infectivity in the amplified samples as PMCA CWD prions.
Author Summary
Prions are unique pathogens that result from conversion of
a normal host-encoded prion protein, PrPC, into a self-
propagating, disease-associated conformation, referred to
as PrPSc. An important aspect of prion diseases is their
transmissibility, frequently as epidemics. The contagious
transmission of chronic wasting disease (CWD) of deer and
elk is of particular concern. The elements governing prion
transmission between species, including the influence of
agent strain properties, remain enigmatic, in large part
because of considerable difficulties associated with exper-
imental manipulation of prions. The aim of this study was
to evaluate the feasibility of expediting studies of intra-
and inter-species prion transmission. We made use of
transgenic mice as a source of deer prion protein for the
production of CWD prions by protein misfolding cyclic
amplification (PMCA). Characterization of infectivity in the
same transgenic mice demonstrated that PMCA results in
the efficient amplification of CWD prions with unaltered
strain characteristics. Also, whereas adaptation of mouse
prions to form novel cervid prions required several
hundred days and subsequent stabilization in transgenic
mice, we show that PMCA rapidly abrogated this inter-
species transmission barrier. Our results indicate that
PMCA can be used to replace the process of prion strain
adaptation and selection occurring in vivo.
Accelerated Prion Propagation
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Concordant strain properties of PMCA-derived and
naturally occurring CWD prions
In order to fully evaluate the biochemical and neuropatholog-
ical characteristics of disease induced by both inocula, we
performed detailed comparative studies of the brains of mice
infected with naturally occurring and PMCA CWD prions. The
similar incubation times of naturally occurring and PMCA CWD
prions (Fig. 2) raised the possibility that the strain properties of the
04-22412 CWD prion isolate were maintained during serial
PMCA. Consistent with this notion, the electrophoretic mobilities
(Fig. 3A) and glycosylation profiles of CerPrPSc produced in the
brains of Tg(CerPrP)1536+/2 mice inoculated with both prepa-
rations were similar (Fig. 3D).
Assessment of the neuroanatomical distribution of PrPSc by
histoblotting is another parameter that has been used to
characterize prion strains [20,21,32,41,42]. The appearance and
distribution of CerPrPSc throughout histoblotted brain sections of
diseased Tg(CerPrP)1536+/2 mice infected with 04-22412 CWD
(Fig. 4A) or PMCA CWD prions (Fig. 4B) were similar (n = 1 in
each group). Markedly punctate accumulations of CerPrPSc were
present in histoblotted brain sections of mice infected with both
naturally occurring and PMCA CWD prions, either prior to, or
following treatment with proteinase K (PK). CerPrPSc-containing
aggregates often coalesced into larger immunoreactive structures.
Similar aggregation and distribution of CerPrPSc has been
reported in Tg(CerPrP)1536+/2 mice infected with various
naturally occurring deer and elk CWD isolates [30,32].
The accumulation of CerPrPSc in plaques was confirmed by
immunohistochemical analyses of brains from diseased
Tg(CerPrP)1536+/2 mice infected with naturally occurring
CWD prions (Fig. 5B and C) and PMCA CWD prions (Fig. 5D
and E). The distribution of immunoreactive plaques and
accompanying spongiform degeneration was similar in both cases
(Fig. 5B–E), with plaques often coalescing into larger structures
frequently bordered by vacuoles (Fig. 5E).
Previous studies showed the unfolding characteristics of PrPSc to
be a sensitive and quantitative means of assessing strain-dependent
differences in PrPSc conformation [11,12,32,43]. We therefore
determined the relative stabilities of CerPrPSc in the brains of
Tg(CerPrP)1536+/2 mice infected with PMCA-generated or in
vivo-derived CWD prions. Brian extracts were treated with
increasing concentrations of guanidine hydrochloride (GdnHCl),
Figure 1. Western blot analysis showing amplification of protease-resistant CerPrP by serial PMCA. A: Serial PMCA of 04-22412 CWD
using Tg(CerPrP)1536+/2 brain homogenate. CWD prions in a 10% brain homogenate of diseased mule deer 04-22412 were diluted 10-fold into 10%
brain homogenate from perfused Tg(CerPrP)1536+/2 mice. Following a round of PMCA, the sample, containing amplified protease-resistant CerPrP,
was diluted 10-fold into 10% brain homogenate from perfused Tg(CerPrP)1536+/2 mice for a further round of PMCA. This process of serial PMCA was
repeated for 22 rounds. PK-treated samples from each of the first 10 rounds were analyzed by Western blotting. In the final lane, a sample from Tg
brain homogenate without PK treatment was loaded. B: Serial PMCA of RML using Tg(CerPrP)1536+/2 brain homogenate. Mouse RML prions in a 10%
brain homogenate from a diseased wild type FVB mouse were diluted 10-fold into 10% brain homogenate from perfused Tg(CerPrP)1536+/2 mice.
Serial PMCA was repeated for 22 rounds. PK-treated samples from each of the first 7 rounds were analyzed by Western blotting. The unamplified RML
seed that produced protease-resistant PrP following PMCA in round 1 was loaded in the first lane, while a sample from Tg brain homogenate without
PK treatment was loaded in the final lane. C: Western blot quantification of protease-resistant PrP in inocula used to challenge Tg(CerPrP)1536+/2
mice. Samples were PK-treated as indicated. Ratios indicate the fold dilution of the original preparation. In the final lane, a sample from CWD brain
homogenate without PK treatment was loaded.
doi:10.1371/journal.ppat.1000139.g001
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followed by PK digestion and analysis of residual CerPrPSc by
Western blotting. When plotted, the mean amounts of PK-resistant
PrP in the brains of three diseased Tg(CerPrP)1536+/2mice at each
concentration of denaturant, formed sigmoidal curves. The
transition point at the concentration where half the CerPrPSc in
the samples was denatured is referred to as the mean GdnHCl1/2
value. Similar denaturation properties and mean GdnHCl1/2 values
indicated comparable CerPrPSc stabilities following infection with
04-22412 CWD and PMCA CWD prions (Fig. 6A and B).
Collectively, the concordant clinical and histological profiles of
Tg(CerPrP)1536+/2 mice infected with naturally occurring and
PMCA-derived CWD prions, as well as the similar biochemical
properties of the resulting CerPrPSc, indicate that the characteristics
of 04-22412 CWD prions were maintained during serial PMCA.
Interspecies transmission of mouse RML prions in
Tg(CerPrP) mice results in variable CNS disease
While deer and elk CWD prions propagated efficiently in
Tg(CerPrP)1536+/2 mice, with 100% rates of transmission and
mean incubation times ranging from ,225 to 270 d, our previous
studies showed that Tg(CerPrP)1536+/2 mice remained free of
prion disease for .1 year after infection with mouse RML prions
[30]. To fully characterize the extent of this transmission barrier,
we challenged additional Tg(CerPrP)1536+/2 mice with mouse
RML prions and extended our observations beyond one year.
While all RML-inoculated Tg(CerPrP)1536+/2 mice (n= 9)
eventually developed clinical signs, the time to disease onset was
protracted and highly variable (mean incubation time, 489622 d;
range of disease onset ,400 to 590 d) (Fig. 2). In contrast to the
predominantly monoglycosylated profile of mouse PrPSc in the
brains of RML infected wild type FVB mice (Figs. 1C, 3B and 3D),
CerPrPSc produced in the brains of RML infected
Tg(CerPrP)1536+/2 mice was predominantly diglycosylated
(Fig. 3B, C and D). This suggested that adaptation of mouse
RML prions occurred following transit across a species barrier in
mice expressing CerPrPC.
Histoblot analysis revealed variable distribution and aggregation
of CerPrPSc in the CNS of two diseased Tg(CerPrP)1536+/2 mice
infected with mouse RML prions (Fig. 7). The deposition of
CerPrPSc in the brain of Tg(CerPrP)1536+/2 mouse #4825, which
developed disease 512 d after infection, was widespread and diffuse.
In contrast, CerPrPSc in the brain of Tg(CerPrP)1536+/2 mouse
#5302, which developed disease after 488 d, accumulated in small,
discrete plaques. The punctate staining observed in mouse #5302
differed from the CerPrPSc aggregates in Tg(CerPrP)1536+/2 mice
infected with naturally occurring or PMCA CWD prions (Fig. 4),
which were deposited in different brain regions, and frequently
coalesced into larger immunoreactive structures. Immunohisto-
chemical analysis of additional RML-infected Tg(CerPrP)1536+/2
mouse brains confirmed that CerPrPSc deposition and aggregation
varied between animals. While diffuse CerPrPSc staining character-
ized the CNS of animal #5297 (Fig. 5G), CerPrPSc accumulated in
small plaques in the CNS of animal #5300 (Fig. 5H).
Abrogation of the transmission barrier to mouse prions
in Tg(CerPrP) mice produces novel cervid-adapted prions
with properties distinct from CWD
The brain of Tg(CerPrP)1536+/2 mouse #4827 that developed
disease 394 d after infection with mouse RML prions was prepared
for serial transmission studies. Infectivity in the brain of this mouse,
referred to as Cer/RML-4827 prions, induced disease in
Tg(CerPrP)1536+/2 mice (n=8) with a mean incubation time of
14865 d (Fig. 2). This substantial reduction in time to onset of
disease, as well as the narrow range of incubation times on second
passage, is characteristic of prion adaptation following transit across
a species barrier. The diglycosylated CerPrPSc pattern that
characterized infection of Tg(CerPrP)1536+/2 mice with mouse
RML prions was maintained upon passage of Cer/RML-4827
prions to Tg(CerPrP)1536+/2 mice (Fig. 3C and D). Histoblot
analysis of a recipient Tg(CerPrP)1536+/2 mouse brain #7263
showed that infection with Cer/RML-4827 prions was characterized
by diffuse rather than punctate CerPrPSc distribution (Fig. 7).
The denaturation profile of CerPrPSc in the brains of
Tg(CerPrP)1536+/2 mice infected with Cer/RML-4827 prions
differed from mouse PrPSc in the brains of RML-infected FVB
mice (mean GdnHCl1/2 values of 1.27 M and 1.57 M respectively,
Figure 2. Generation and characterization of PMCA-derived prions using Tg(CerPrP)1536+/2 mice. Each symbol represents an individual
mouse. Closed symbols indicate diseased mice and open symbols indicate asymptomatic mice. Green symbols indicate prions originating from CWD;
blue symbols indicate prions originating from RML; circles indicate in vivo-derived prions; squares indicate PMCA-derived prions. The blue circle
surrounded by the red square signifies mouse #4827 that was the origin of Cer/RML-4827 prions, while the green and blue squares signify mice
#5302 and #4825 respectively, the brains of which were analyzed by histoblotting. Incubation times are expressed as the mean6standard error of
the mean; listed in parenthesis is number of diseased mice/ number of mice inoculated.
doi:10.1371/journal.ppat.1000139.g002
Accelerated Prion Propagation
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Fig. 6C and D). This conformational difference is consistent with
adaptation of mouse RML prions following replication in
Tg(CerPrP)1536+/2 mice. Moreover, the denaturation profile of
CerPrPSc produced in response to infection with Cer/RML-4827
prions was considerably different from the profiles of CerPrPSc
produced following infection with naturally occurring or PMCA-
derived CWD prions (mean GdnHCl1/2 values of 1.27 M and
2.7–2.8 M respectively, Fig. 6A and B). This indicated that
adaptation of mouse RML prions in Tg(CerPrP)1536+/2 mice
resulted in the formation of novel cervid prions with a
conformation distinct from CWD.
Formation and characterization of PMCA-derived cervid
adapted RML prions
We investigated whether PMCA could abrogate the barrier to
mouse RML prion transmission that was ultimately breached
following adaptation in Tg(CerPrP)1536+/2 mice. Brain homog-
enates from uninfected Tg(CerPrP)1536+/2 mice were seeded with
mouse RML prions and 22 rounds of serial PMCA were
performed as before. Protease-resistant CerPrP was amplified to
high levels during each round of serial PMCA, culminating in 22
rounds (Fig. 1B and C). The change in PrPSc glycoform pattern
that occurred following passage of mouse RML prions from wild
type to Tg(CerPrP)1536+/2 mice (Fig. 3B and D) also appeared to
be a feature of RML adaptation during serial PMCA, with
protease-resistant CerPrP becoming predominantly diglycosylated
at round 2 and thereafter (Fig. 1B). No protease-resistant PrP was
produced in the absence of prion seeds after 10 rounds of serial
PMCA of six duplicated samples of a healthy Tg(CerPrP)1536+/2
brain extract (data not shown).
Remarkably, inoculation of Tg(CerPrP)1536+/2 mice with this
PMCA-adapted material, rapidly induced disease in all inoculated
Tg(CerPrP)1536+/2 mice (n= 7). The 14366 d mean incubation
time was strikingly similar to the ,150 d mean incubation time of
Cer/RML-4827 prions that resulted from adaptation of RML
prions following replication in Tg(CerPrP)1536+/2 mice (Fig. 2).
This indicated that the barrier to inter-species transmission of
mouse RML prions, which requires several hundred days of
Figure 3. Characteristics of PrPSc produced in Tg(CerPrP)1536+/2 mice. A: Western blot showing accumulation of CerPrPSc in the brains of
diseased Tg(CerPrP)1536+/2 mice inoculated with CWD or PMCA CWD prions. B: Western blot comparison of PrPSc in the brains of diseased FVB and
Tg(CerPrP)1536+/2 mice (Tg1536) inoculated with mouse RML prions. C. Western blot showing CerPrPSc accumulation in Tg(CerPrP)1536+/2 mice
infected with mouse RML prions, Cer/RML-4827, and PMCA Cer/RML prions. D: Ratio of three protease-resistant PrP glycoforms produced in the
brains of diseased Tg(CerPrP)1536+/2mice or FVB mice. Data points represent the mean relative proportions of di-, mono-, and un-glycosylated PrP as
a percentage derived from densitometric quantification of PrPSc in brains of three individual diseased mice in each case. Error bars indicate the
standard error of the mean which, in some cases, was smaller than the symbols used. Samples for Western blot analysis were either untreated (2) or
treated (+) with PK and 50 mg and 100 mg of total protein was loaded for untreated and treated samples respectively. The positions of protein
molecular mass markers at 37, 25 and 20 kDa (from top to bottom) are shown.
doi:10.1371/journal.ppat.1000139.g003
Accelerated Prion Propagation
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adaptation in Tg(CerPrP) mice and stabilization on serial passage,
can be directly bypassed by serial PMCA of RML using CerPrPC
from Tg mouse brain. We therefore refer to infectivity in this
amplified sample as PMCA Cer/RML prions.
Using Western blotting, conformational stability assays, and
histoblotting we characterized the properties of CerPrPSc produced
in the brains of diseased Tg(CerPrP)1536+/2 mice infected with
PMCA Cer/RML prions. The diglycosylated profile of CerPrPSc
in the PMCA Cer/RML inoculum (Fig. 1C) was maintained in the
brains of diseased Tg(CerPrP)1536+/2 mice (Fig. 3C and D). The
denaturation profile and mean GdnHCl1/2 value of CerPrP
Sc in
the brains of Tg(CerPrP)1536+/2 mice infected with PMCA Cer/
RML prions was equivalent to Cer/RML-4827, but different from
RML in wild type FVB mice or from naturally occurring or
PMCA-derived CWD prions in Tg(CerPrP)1536+/2 mice. This
indicated that, similar to the adaptation of RML in
Tg(CerPrP)1536+/2 mice, serial PMCA resulted in adaptation of
mouse RML prions to produce novel cervid prions with a CerPrPSc
conformation distinct CWD prions. Histoblotting revealed a
consistent pattern of CerPrPSc distribution in the brains of two
Tg(CerPrP)1536+/2 mice infected with PMCA Cer/RML prions
(Fig. 7). The diffuse CerPrPSc deposition in the brains of two such
mice, referred to as#5294 and#5295, was distinct from the small
punctate staining pattern in the CNS of Tg(CerPrP)1536+/2
#5302 mouse infected with RML, or the large CerPrPSc deposits in
the CNS of Tg(CerPrP)1536+/2 mice infected with CWD prions
(Fig. 4). Comparison of the histoblot patterns in#5294 and#5295
mice with Tg(CerPrP)1536+/2 mouse #7263 that was infected
with Cer/RML-4827 prions also revealed subtle differences in the
regional distribution of CerPrPSc with, for example, relative sparing
of the corpus callosum in the#5294 and#5295 mice infected with
PMCA Cer/RML prions (Fig. 7). These differences in CerPrPSc
distribution suggest that subtle strain differences distinguish Cer/
RML-4827 and PMCA Cer/RML prions.
Figure 4. Regional distribution of CerPrP in the CNS of diseased Tg(CerPrP)1536+/2 mice infected with CWD or PMCA CWD prions.
PK-treated (+) or untreated (2) histoblotted coronal sections, as indicated, of terminally sick Tg(CerPrP)1536+/2 mice inoculated with A, naturally
occurring CWD prions from mule deer isolate 04-22412 or B, PMCA-derived CWD prions. Histoblots were stained with Hum-P anti-PrP recombinant
Fab followed by alkaline phosphatase-conjugated goat anti-human secondary antibody.
doi:10.1371/journal.ppat.1000139.g004
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Collectively, the similar rapid incubation times of PMCA Cer/
RML and Cer/RML-4827 prions, and the distinctive properties of
the resulting CerPrPSc, demonstrate that both processes produced
novel cervid prions with biological properties distinct from CWD.
Our findings therefore indicate that serial PMCA substituted for the
long-term process of RML prion adaptation in Tg(CerPrP)1536+/2
mice. Nonetheless, our histoblotting and immunohistochemical
analyses show that adaptation of RML prions in
Tg(CerPrP)1536+/2 mice resulted in the formation of at least two
distinct isolates, and that PMCA adaptation likely resulted in a third.
These observations indicate that multiple isolates with different
strain properties may be produced during the process of prion
adaptation following inter-species transmission.
Discussion
Accelerated high fidelity intra-species prion amplification
The studies reported here are significant in showing that PrPSc
and CWD prion infectivity from diseased deer brain are faithfully
reproduced in vitro by PMCA using CerPrPC from the brains of
Tg(CerPrP)1536+/2 mice as the substrate for amplification. They
extend previous reports using Tg(CerPrP)1536+/2 mice [44] by
showing that PMCA-derived CWD prions induce disease and the
production of CerPrPSc in Tg(CerPrP) mice as efficiently as prions
isolated from the CNS of deer with CWD.
Tg mice represent a convenient, controlled source of PrPC for
PMCA with significant advantages over PrPC from animals or
Figure 5. Immunohistochemical detection of CerPrPSc and spongiform degeneration in the brains of diseased Tg(CerPrP)1536+/2
mice. A, B, and D are sections through the hippocampus of non-diseased or diseased Tg(CerPrP)1536+/2mice; section C is from the cerebral cortex.
A, absence of spongiform pathology and immunohistochemically-reactive PrP in the hippocampus of an asymptomatic PBS-inoculated
Tg(CerPrP)1536+/2 mouse; B, accumulation of plaques in the hippocampus of diseased Tg(CerPrP)1536+/2 mouse inoculated with naturally
occurring 04-22412 CWD prions; C, accumulation of plaques in the cerebral cortex of a diseased Tg(CerPrP)1536+/2 mouse inoculated with naturally
occurring 04-22412 CWD prions; D, accumulation of plaques in the hippocampus of diseased Tg(CerPrP)1536+/2 mouse inoculated with PMCA CWD
prions; E, high magnification of a large plaque aggregate rimmed by vacuoles; F, absence of spongiform pathology and immunohistochemically
reactive PrP in the medulla of asymptomatic PBS-inoculated Tg(CerPrP) 1536+/2 mouse; G, diffuse PrP accumulation in the medulla of diseased
Tg(CerPrP)1536+/2 mouse #5297 inoculated with mouse RML prions; H, high magnification of a section thought the hippocampus of diseased
Tg(CerPrP)1536+/2 mouse #5300 showing PrP accumulation in small plaques; I, diffuse PrP accumulation in the medulla of a diseased
Tg(CerPrP)1536+/2 mouse inoculated with PMCA Cer/RML prions. Hematoxylin was used as counterstain. Bar = 100 mm in A–D; Bar = 50 mm in E–I.
doi:10.1371/journal.ppat.1000139.g005
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humans. Any form of transgene-derived PrP, either mutated or
PrPC from different species, can be readily overexpressed on a
Prnp0/0 background, and the brains of Tg mice can be
appropriately prepared for use in PMCA. Underscoring this
concept, brain homogenate from Tg mice expressing human PrP
was recently used to amplify PrPSc from the brains of variant CJD
patients by PMCA [45]. As we show here, Tg mice also provide a
crucial additional resource in which to fully characterize the
biological properties of PMCA-derived prions. These studies raise
the prospect of using PMCA and Tg mice expressing mutant and
wild type PrP, and polymorphic variants thereof, from cervids,
humans, cattle, sheep, rodents, horses, and other mammals, to
characterize the strain and host-range properties of naturally
occurring prion strains.
Our studies not only reassuringly support previous demonstrations
that serial PMCA reproduces experimentally-adapted scrapie 263K
prions [38,46], but also demonstrate (to our knowledge for the first
time) cell-free amplification of naturally occurring prion infectivity.
Previous serial PMCA of the 263K isolate resulted in the generation
of prions with apparently lower specific infectivity than brain-derived
infectious material [38,46]. Here we show that the mean incubation
times of naturally occurring 04-22412 CWD and PMCA-derived
CWD prion preparations in Tg(CerPrP)1536+/2 mice were
comparable. Since each inoculum comprised similar amounts of
CerPrPSc, this suggests that equivalent levels of CWD prion
infectivity were present in each case. While the reason for the
discrepant behavior of 263K and 04-22412 CWD prions is
unknown, the suggestion that PMCAmay have generated a different
prion strain after repeated in vitro amplification of 263K prions [38]
appears unlikely in the case of PMCA of CWD prions.
To analyze and compare the strain properties of PMCA CWD
and naturally occurring CWD prions we analyzed several
independent criteria previously used to characterize prion strains.
These included the induction of clinical signs in mice, the
electrophoretic migration and glycoprofiles of CerPrPSc by
Western blotting, PrPSc deposition by histoblot, cerebral vacuol-
ization and PrPSc deposition by immunohistochemistry, and the
denaturation characteristics of PrPSc. Based on these criteria, it
appears that PMCA CWD prions retain the biological and
biochemical properties of the originating CWD prions. However,
we realize that each approach is limited in its ability to
unequivocally define strain variation. For example, subtle
Figure 6. Assessment of the conformational stability of PrPSc in the brains of diseased mice. In A and C, densitometric analysis of
immunoblots shows the percentage of protease-resistant CerPrPSc as a function of GdnHCl concentration. The sigmoidal dose-response was plotted
using a four-parameter algorithm and non-linear least-square fit. Each point shown is the mean value derived from densitometric quantification of
PK-resistant PrP in three diseased Tg(CerPrP)1536+/2 mouse brain extracts in each study group. Error bars indicate the standard error of the mean
which, in some cases, was smaller than the size of the symbols used to indicate the mean. A, Tg(CerPrP)1536+/2 mice inoculated with 04-22412 CWD
prions (green filled circles), or PMCA-derived CWD prions (green filled squares); C, Tg(CerPrP)1536+/2mice inoculated with Cer/RML-4827 prions (blue
filled circles), or PMCA Cer/RML prions (blue filled squares). For comparison, the conformational stability of MoPrPSc in the brains of wild type FVB
mice infected with RML prions is shown (black diamonds). In B and D, representative immunoblots of protease-resistant PrP following PK treatment
are shown. The mean GdnHCl1/2 value, representing the concentration at which half the PrP
Sc in each series was denatured, is also shown.
doi:10.1371/journal.ppat.1000139.g006
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differences in the pattern of PrPSc deposition in histoblots of
individual mice may result from slight variances in the locations of
coronal sections between mice, or from the times at which mice
were sacrificed. The sensitive and specific paraffin-embedded
tissue (PET) blot technique [47] may provide finer resolution for
future comparative analyses. Furthermore, while the indistinguish-
able denaturation profiles and GdnHCl1/2 values of CerPrP
Sc in
the brains of Tg mice dying from infection with naturally
occurring or PMCA-derived CWD prions suggests comparable
CerPrPSc structures, equivalent conformational stability does not
necessarily indicate invariant conformations at all structural levels.
Other approaches may reveal evidence of PrPSc structural
differences. For example, infrared-spectroscopy distinguished the
secondary structures of protease-resistant PrP from two hamster
scrapie strains when immunobiochemical typing failed to detect
differences [48]. Fourier transform infrared-spectroscopy was also
used to compare secondary structures of PMCA-generated and
brain-derived protease-resistant PrP [38] as well as protease-
resistant PrP products from seeded polymerization of recombinant
PrP (rPrP-PMCA) [49].
Production of novel strains following abrogation of prion
transmission barriers
Strain adaptation experiments, traditionally performed in vivo,
often require years to generate prions with stable biological
properties. While investigating the susceptibility of Tg mice to
prions from other species provides a feasible approach to address
the potential for inter-species prion transmission, the studies
reported here demonstrate that abrogating the barrier to mouse
RML prion transmission in Tg(CerPrP) mice required several
hundred days followed by strain stabilization after serial passage.
Our previous studies showed that Tg(CerPrP)1536+/2 are also
susceptible to sheep SSBP/1 scrapie prions, but with apparently
less of a transmission barrier than mouse RML prions [32].
An important sequel to inter-species prion transmission is
frequently the acquisition of new strain properties. The different
patterns of CerPrPSc deposition in diseased Tg(CerPrP)1536+/2
mice following RML infection indicates that abrogation of this
transmission barrier most likely results in the formation and
propagation of different prion isolates in individual mice. In this
case we observed two general patterns by histoblotting and
Figure 7. Regional distribution of CerPrP in the CNS of diseased Tg(CerPrP)1536+/2 mice infected with mouse RML prions, in vivo-
adapted Cer/RML prions, and PMCA-adapted Cer/RML prions. PK-treated histoblotted coronal sections though, from top to bottom, the
region of the septum, hippocampus, anterior midbrain, posterior midbrain, pons, and oblongata from diseased Tg(CerPrP)1536+/2 mice inoculated
with mouse RML prions, Cer/RML-4827, or PMCA Cer/RML prions. Sections were prepared from two different Tg(CerPrP)1536+/2 mice inoculated with
mouse RML prions (#4825 and #5302) and two different Tg(CerPrP)1536+/2 mice inoculated with PMCA Cer/RML prions (#5294 and #5295). Lateral
areas of the posterior midbrain section of mouse #4825 were lost during tissue processing. Histoblots of sections through the anterior and posterior
midbrain from an asymptomatic age-matched Tg(CerPrP)1536+/2 mouse inoculated with PBS, shown to the left, demonstrate the specificity of
immunostaining with Hum-P anti-PrP recombinant Fab.
doi:10.1371/journal.ppat.1000139.g007
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immunohistochemistry: diffuse CerPrPSc deposition in mice
#4825 and #5297; and small plaque deposits in the case of mice
#5302 and #5300. Materials from the histoblotted #4825 and
#5302 mice were not available for serial transmission studies. At
the time of writing, serial transmissions of prions from the brains of
mice #5297 and #5300 are ongoing. The brain of mouse #4827
was used for serial transmission and full strain characterization in
Tg(CerPrP)1536+/2 mice. The substantial reduction and consis-
tent time to onset of disease following serial passage of Cer/RML-
4827 prions is characteristic of prion adaptation following transit
across a species barrier. The ,150 d mean incubation period of
Cer/RML-4827 prions is ,100 days shorter than either CWD or
PMCA-generated CWD prions (Fig. 2), indicating adaptation of
RML in Tg(CerPrP)1536+/2 mice and the production of novel
cervid prions with biological properties distinct from CWD.
Additional detailed comparisons with Tg(CerPrP) mice infected
with either naturally occurring or PMCA CWD prions were
consistent with the notion that the biological properties of Cer/
RML-4827 prions were distinct from CWD. In accordance with
previous studies of experimentally-adapted hamster prion isolates
in Tg mice expressing artificial chimeric PrP genes, which
indicated that a change in the conformation of PrPSc accompanied
the emergence of a new prion strain [11], the conformational
stability of PrPSc changed following passage of mouse RML prions
from wild type mice and subsequent adaptation to form Cer/
RML-4827 prions in Tg(CerPrP)1536+/2 mice (Fig. 6). Also in
accordance with the process of prion adaptation, the profile of
RML PrPSc glycosylation changed following transmission to
Tg(CerPrP)1536+/2 mice (Fig. 3), and there were distinct
differences in the morphology and neuroanatomical distribution
of PrPSc in Tg(CerPrP)1536+/2 mice infected with Cer/RML-
4827 and CWD prions.
We show that the adaptation of mouse RML prions, which
required two passages in Tg(CerPrP) mice, can be accomplished
by in vitro amplification of CerPrPC with heterologous RML
prions to create cervid adapted RML prions in a matter of weeks.
Accompanying this adaptation, the RML glycopattern changed
from predominantly mono- to diglycosylated PrPSc, which is the
form of CerPrPSc propagated in Tg(CerPrP) mice infected with
RML, Cer/RML-4827 prions, and PMCA Cer/RML prions.
Whereas 22 rounds were used to ensure the elimination of residual
prion seed in the initial round of PMCA, it seems likely that
PMCA-mediated inter-species transmissions can be accomplished
with many fewer rounds of serial PMCA. Whether PMCA-
mediated adaptation occurs with structural intermediates similar
to the process in vivo is currently not known; however, since the
properties of the initiating and resulting prions are, in most cases,
likely to be distinct, it should be possible to determine the kinetics
of prion adaption at each PMCA round. Should it be possible to
reproducibly manipulate the extent of prion adaptation by varying
the number of rounds of serial PMCA, then mechanistic studies of
prion adaptation following inter-species transmission are likely to
be considerably expedited by this approach.
Our studies convincingly show that PMCA of murine RML
prions using Tg(CerPrP)1536+/2 brain homogenate generates a
novel strain of cervid-adapted prions with properties distinct from
either naturally occurring or PMCA-generated CWD prions. It
currently is less clear whether the PrPSc structures and strain
properties of amplified and in vivo derived prions are equivalent.
Direct comparisons of the strain properties of PMCA Cer/RML
cervid prions and in vivo-adapted strains are complicated by our
observations that in vivo adaptation gives rise to individual isolates
with different strain-related properties, at least as judged by
histoblot and immunohistochemical profiles of PrPSc. While
certain strain-related attributes, including comparably rapid prion
incubation times, and similar denaturation profiles of CerPrPSc
after infection, suggest shared biological properties between Cer/
RML-4827 and PMCA Cer/RML prions, other differences,
including targeting of cerebral PrPSc deposition of
Tg(CerPrP)1536+/2 mice infected with Cer/RML-4827 and
PMCA Cer/RML prions, point to divergent strain properties
and thus would rather argue for different strains. Whether inter-
species PMCA-mediated prion adaptation also results in the
generation of multiple and distinct prion strains remains to be
determined, but our limited analyses consisting of uniform
histoblot profiles, reproducible onsets of disease, and similar
conformation stabilities of CerPrPSc in individual infected mice
may indicate that PMCA selectively and stably propagates distinct
strains following abrogation of a species barrier.
Finally, we note that under certain conditions, PMCA may
result in the spontaneous formation of PK-resistant PrP species
[40] and de novo generated infectivity under conditions that do
not involve seeding with infectious prions [50]. While it would be
of considerable interest to determine the biological properties of
spontaneously-produced cervid prions by PMCA of CerPrPC, we
feel that the possibility of spontaneous generation of infectivity in
the context of the current studies is remote. The experiments of
Deleault and co-workers using purified PrPC plus poly(A) RNA,
indicated that spontaneous generation of PrPSc was a stochastic
and relatively infrequent event, estimated at ,1 conversion event
per 661011 input PrPC molecules per PMCA round. Consequent-
ly, amplification of preexisting PrPSc molecules was considered an
unlikely origin for PrPSc formation under these conditions. In
contrast, in the studies reported here where PMCA reactions were
seeded with either CWD or RML prions, high levels of protease-
resistant PrP were amplified at each round of serial PMCA and
remained consistently so during both intra- and inter-species
PMCA-mediated prion amplification (Fig. 1A and B). In control
experiments using unseeded healthy Tg(CerPrP)1536+/2 brain
extract, 10 passages of serial PMCA failed to generate protease-
resistant PrP (data not shown). While we have also spontaneously
generated PrPSc without the addition of prion seeds (Soto and co-
workers, unpublished results; Castilla and co-workers, unpublished
results), the PMCA conditions required to accomplish this
required modification from the standard PMCA conditions used
in the current and previous studies. Standard serial PMCA
conditions in which healthy hamster brain homogenate was
serially diluted into itself in the absence of prion seed failed to
produce protease-resistant PrP following the same number of
PMCA cycles which resulted in amplification of hamster 263K
prions [38]. In a larger experiment, samples of healthy brain
homogenate from 10 different mice and hamsters were subjected
to serial rounds of PMCA amplification in the absence of PrPSc
seed using the PMCA conditions used in study. Following 20
rounds of serial PMCA, we did not observe de novo formation of
PrPSc, nor did these materials, when inoculated into wild-type
animals, induce disease after .400 d (Soto and co-workers,
unpublished observations). For these reasons we feel that the
generation of PrPSc and cervid prions reported in the present
study, when normal brain homogenate from Tg(CerPrP)1536+/2
mice was mixed with prion seeds, is unlikely to be influenced by
spontaneous, de novo generated infectivity.
Materials and Methods
Preparation of tissue homogenates for PMCA
Healthy Tg(CerPrP)1536+/2 mice were perfused with phos-
phate-buffered saline (PBS) plus 5 mM EDTA immediately prior
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to harvesting the tissue. Ten % brain homogenates (w/v) were
prepared in conversion buffer which consisted of PBS containing
NaCl 150 mM, 1.0% Triton X-100, and the completeTM cocktail
of protease inhibitors (Roche, Mannheim, Germany). The samples
were clarified by a brief, low-speed centrifugation (1500 rpm for
30 s) using an Eppendorf centrifuge (Hamburg, Germany).
Serial replication of prions in vitro by PMCA
A 1:10 dilution of 10% brain homogenate from clinically sick
04-22412 infected mule deer or RML infected mice was diluted
into a 10% brain homogenate from Tg(CerPrP)1536+/2 mice.
Samples in 0.2 ml PCR tubes were positioned on an adaptor
placed on the plate holder of a microsonicator (Misonix Model
3000, Farmingdale, NY). Each PMCA cycle consisted of 30 min
incubation at 37uC followed by a 20 s pulse of sonication set at
potency of 7. Samples were incubated without shaking immersed
in the water of the sonicator bath. After a round of 36 cycles, a
10 ml aliquot of the amplified material was diluted into 90 ml of
additional Tg(CerPrP)1536+/2 mouse brain homogenate and a
new round of 36 PMCA cycles was performed. This procedure
was repeated for 22 rounds. The detailed protocol for PMCA,
including reagents, solutions and troubleshooting, has been
published elsewhere [39,51–53].
Production and characterization of transgenic mice, and
sources and preparation of inocula
Tg mice expressing deer PrP, referred to as Tg(CerPrP)1536
have been described previously [30]. While we showed that CWD
prion incubation times are more rapid in Tg(CerPrP)1536
homozygous for the transgene array than hemizygous
Tg(CerPrP)1536 mice [30], because of difficulties associated with
breeding homozygous Tg(CerPrP)1536 mice we have maintained
this line in the hemizygous state by breeding with Prnp0/0 mice.
Such mice are therefore referred to as Tg(CerPrP)1536+/2 mice.
CWD prions were derived from a diseased female mule deer,
referred to as 04-22412 UWVS ESW/JEJ, but abbreviated here as
04-22412. The animal was homozygous for the polymorphic
codon 225, encoding serine at this location. The RML isolate was
originally a kind gift from Byron Caughey (Laboratory of
Persistent Viral Diseases, Rocky Mountain Laboratories, Hamil-
ton, MT) and was passaged by intracerebral inoculation of inbred
FVB/N mice at the University of Kentucky.
Ten % (w/v) homogenates, in phosphate buffered saline (PBS)
lacking calcium and magnesium ions, of cervid and mouse brains
were prepared by repeated extrusion through an 18 gauge
followed by a 21 gauge syringe needle.
Determination of Incubation Periods
Groups of anesthetized mice were inoculated intracerebrally with
30 ml of 1% (w/v) brain extracts prepared and diluted in PBS, or 1%
v/v of the final PMCA product diluted in PBS. Inoculated mice were
diagnosed with prion disease following the progressive development
of at least three signs including truncal ataxia, ‘plastic’ tail, loss of
extensor reflex, difficulty righting, and slowed movement. The time
from inoculation to the onset of definitive and subsequently
progressive clinical signs is referred to as the incubation time.
Analysis of PrP in CNS
For PrP analysis in brain extracts, total protein content from 10%
brain homogenates prepared in PBS was determined by bicincho-
ninic acid (BCA) assay (Pierce Biotechnology Inc., Rockford, IL).
Brain extracts were either untreated or treated with 40 mg/ml PK
for one hour at 37uC in the presence of 2% sarkosyl. Protease
digestion was terminated with 4 mM phenyl methyl sulfonyl fluoride
(PMSF). Proteins were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). Proteins thus
resolved were electrophoretically transferred to PVDF-FL mem-
branes (Millipore, Billerica, MA). Membranes were probed with
mAb 6H4 [54], or the Hum-P anti-PrP recombinant Fab [55]
followed by horse radish peroxidase-conjugated sheep anti-mouse
IgG or goat anti-human secondary antibody respectively. Signal was
developed using ECL-plus detection (Amersham), and analyzed
using a FLA-5000 scanner (Fuji).
Histoblots of 10 mm thick cryostat sections were generated and
transferred to nitrocellulose as previously described [41]. Histo-
blots were immunostained with the Hum-P anti-PrP recombinant
Fab followed by alkaline phosphatase-conjugated goat anti-human
secondary antibody. Images were captured using a Nikon
SM21000 microscope with Photometrics Coolsnap CF digital
imager and processed using MetaMorph software
The unfolding characteristics of PrPSc in brain homogenates of
terminally sick mice were analyzed using a Western blot-based
conformational stability assay [12,32,43] which is a modification of
the original ELISA based protocol [11].
Analysis of PrP in the brains of Tg mice by immunohistochem-
istry was performed as previously described [56] using anti-PrP
mAb 6H4 [54] as primary antibody and IgG1 biotinylated goat
anti-mouse secondary antibody (Southern Biotech). Digitized
images for figures were obtained by light microscopy using a
Nikon Eclipse E600 microscope equipped with a Nikon DMX
1200F digital camera.
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